Dr. Higano on Radium-223 for Prostate Cancer

Celestia Higano, MD
Published: Tuesday, Jun 27, 2017



Celestia Higano, MD, professor of Medicine and Urology at the University of Washington, and a member of the Clinical Research Division at Fred Hutchinson Cancer Research Center, discusses radium-223 for patients with prostate cancer.

Radium-223 was shown in a phase III trial to extend survival for patients with prostate cancer, explains Higano. Unlike the other radioisotopes which are used towards the end stage, it was shown that there was a survival benefit for those who received radium-223 in addition to best supportive care.

SELECTED
LANGUAGE


Celestia Higano, MD, professor of Medicine and Urology at the University of Washington, and a member of the Clinical Research Division at Fred Hutchinson Cancer Research Center, discusses radium-223 for patients with prostate cancer.

Radium-223 was shown in a phase III trial to extend survival for patients with prostate cancer, explains Higano. Unlike the other radioisotopes which are used towards the end stage, it was shown that there was a survival benefit for those who received radium-223 in addition to best supportive care.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 2nd Annual International Congress on Oncology Pathology™Aug 31, 20191.5
Publication Bottom Border
Border Publication
x